Brief From our Editor — Replimune (REPL) Stock.

Shares of Replimune have moved 3.8% today, and are now trading at a price of $25.96. In contrast, the S&P 500 index saw a 1.3% change and the Dow Industrial Average posted a 1.0% performance. Today's trading volume is 483,257 compared to the stock's average volume of 393,938.

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. Based in Woburn, United States the company has 206 full time employees and a market cap of $1,291,234,816.

The company is now trading -43.87% away from its average analyst target price of $46.25 per share. The 8 analysts following the stock have set target prices ranging from $34 to $60, and on average give Replimune a rating of strong buy.

Over the last year, REPL shares have gone down by -10.9%, which represents a difference of 4.8% when compared to the S&P 500. The stock's 52 week high is $30.89 per share and its 52 week low is $13.05. With negative earnings per share and negative cahs flows since 2019, Replimune may not have a strong enough business to reverse this trend.

2019-03-31 2020-03-31 2021-03-31 2022-03-31
Earnings Per Share n/a n/a $-1.75 $-2.26
EPS Growth n/a n/a n/a -29.14%
Free Cash Flow $-27,978,000.0 $-67,092,000.0 $-63,781,000.0 $-84,516,000.0
FCF Growth n/a -139.8% 4.94% -32.51%
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.